Anti-Human ITGAV Recombinant Antibody (Abituzumab) (CAT#: TAB-H01)

Figure 4 DI17E6 promotes detachment of prostate cancer cells from vitronectin.

Prostate cancer cell lines (LNCaP, C4-2B, ARCaP, PC3, DU145 and VCaP cells) were seeded on 96-well plates coated with vitronectin.

Jiang, Y. , Dai, J. , Yao, Z. , Shelley, G. , & Keller, E. T. . (2017). Abituzumab targeting of αv-class integrins inhibits prostate cancer progression. molecular cancer research mcr, 15(7), molcanres.0447.2016.

Figure 5 DI17E6 inhibits adhesion of prostate cancer cells on vitronectin.

Prostate cancer cell lines (LNCaP, C4-2B, ARCaP, PC3, DU145 and VCaP cells) were seeded on the 96-well plates pre-coated with fibronectin.

Jiang, Y. , Dai, J. , Yao, Z. , Shelley, G. , & Keller, E. T. . (2017). Abituzumab targeting of αv-class integrins inhibits prostate cancer progression. molecular cancer research mcr, 15(7), molcanres.0447.2016.

Figure 1 Anti-Human ITGAV Recombinant Antibody (TAB-H01) in SDS-PAGE

SDS-PAGE analysis of TAB-H01 in β-mercaptoethanol-reduced (Lane 1) and non-reduced (Lane 2) conditions. Gel stained for 30 minutes with Coomassie Blue. As a result of different reduced proteins (Heavy chain and Light chain) migrate as about 50 kDa and 25 kDa, respectively. And non-reduced protein migrates as 180 kDa.

Figure 2 Anti-Human ITGAV Recombinant Antibody (TAB-H01) in SEC-HPLC

SEC-HPLC analysis of TAB-H01 shows that the purity is more than 95%.

Column: 3 µm, 7.8 x 300 nm
Mobile phase: 150 mM Sodium Phosphate Buffer, pH 7.0
Detection: UV 280 nm
Injection: 10 µl

Figure 3 Anti-Human ITGAV Recombinant Antibody (TAB-H01) in WB

Western blot analysis of TAB-H01 was performed by loading human Integrin alpha V beta 3 protein (His tag) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with TAB-H01 and HRP conjugated Anti-Human IgG as a secondary antibody (1: 2000). Chemiluminescent detection was performed.

Lane 1: Reduced antigen (0.8 μg)

Figure 4 Anti-Human ITGAV Recombinant Antibody (TAB-H01) in DB

Dot Blot analysis of TAB-H01 was performed by coating with human Integrin alpha V beta 3 protein (His tag).

TAB-H01 incubation concentration: 2 μg/mL.
HRP conjugated Anti-Human IgG as a secondary antibody (1: 2000)

Figure 5 Anti-Human ITGAV Recombinant Antibody (TAB-H01) in ELISA

ELISA analysis of TAB-H01 was performed by coating with human Integrin alpha V beta 3 protein (His tag). Then blocked with BSA and incubated with TAB-H01. The HRP conjugated Anti-Human IgG as a secondary antibody (1: 2000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.